Christopher Webster, DO
Internal Medicine · Rochester Hills, MINPI 1437442613
Payments from drug & device makers
Across 503 payments — averaging $223.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$35K
- Bayer$33K
- Boehringer Ingelheim$25K
- AstraZeneca$15K
- Travere Therapeutics, Inc.$664
- Vifor Pharma, Inc.$647
- plus $4K from 24 others
What the payments were for
- Consulting fees$2430%
- Speaking & faculty fees$99,96089%
- Travel & lodging$3,4203%
- Food & beverage$8,2967%
- Education$2800%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 47 | $34,562 |
| Bayer | 48 | $32,695 |
| Boehringer Ingelheim | 50 | $24,910 |
| AstraZeneca(2 entities) | 100 | $15,178 |
| Travere Therapeutics, Inc. | 32 | $664 |
| Vifor Pharma, Inc. | 31 | $647 |
| OPKO Pharmaceuticals, LLC | 37 | $570 |
| Amgen(2 entities) | 26 | $506 |
| Novo Nordisk | 15 | $377 |
| Aurinia Pharma U.S., Inc. | 11 | $316 |
| Calliditas Therapeutics US Inc. | 15 | $306 |
| Novartis | 11 | $216 |
| GSK | 20 | $207 |
| Otsuka America Pharmaceutical, Inc. | 10 | $186 |
| Akebia Therapeutics Inc | 6 | $124 |
| Ardelyx, Inc. | 6 | $119 |
| Fresenius USA Marketing, Inc. | 7 | $111 |
| AMAG Pharmaceuticals, Inc. | 8 | $108 |
| Mallinckrodt Hospital Products Inc. | 6 | $100 |
| Mallinckrodt Enterprises LLC | 3 | $64 |
| Daiichi Sankyo Inc. | 3 | $47 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $35 |
| Apellis Pharmaceuticals, Inc. | 2 | $35 |
| Scpharmaceuticals Inc. | 1 | $22 |
| Kyowa Kirin, Inc. | 1 | $19 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| ANI Pharmaceuticals, Inc. | 1 | $15 |
| Recor Medical Inc | 1 | $14 |
| Ultragenyx Pharmaceutical Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$112,199 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 551 | $482,130 |
| FarxigaDapagliflozin Propanediol | 348 | $280,043 |
| LokelmaSodium Zirconium Cyclosilicate | 73 | $46,615 |
| KerendiaFinerenone | 41 | $41,085 |
| EntrestoSacubitril/Valsartan | 26 | $32,960 |
| DapagliflozinDapagliflozin Propanediol | 14 | $6,909 |
| Potassium Citrate ErPotassium Citrate | 58 | $6,726 |
| Bumetanide | 93 | $6,179 |
| Sevelamer Carbonate | 26 | $4,403 |
| Losartan Potassium | 274 | $3,589 |
| Calcitriol | 91 | $2,491 |
| Calcium Acetate | 17 | $2,186 |
| Nifedipine ErNifedipine | 66 | $2,120 |
| Hydralazine Hcl | 117 | $1,810 |
| Potassium Chloride | 81 | $1,721 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $24,910 | $482,130551 claims |
| AstraZenecaFarxiga, Lokelma | $15,178 | $326,658421 claims |
| BayerKerendia | $32,695 | $41,08541 claims |
| NovartisEntresto | $216 | $32,96026 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $15 | $50311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Rochester Hills
- Ulka VaishampayanAnn Arbor$33.7M
- Jeffrey PottsBay City$14.7M
- Neil FraserTroy$14.3M
- Abdulhassan SaadDearborn$11.5M
- Leslie PelkeyGrand Rapids$8.5M
- Jay SandbergTroy$8.3M
- Ding WangDetroit$6.8M
- Dipenkumar ModiDetroit$4.1M
- Ahmed ArifFlint$4.1M
- Sudipto MukherjeeRoyal Oak$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.